

- **Name:** **Hong Jae Chon**
  - **Current Position & Affiliation:** **Associate Professor**
  - **Country:** **Korea**
- 

- **Educational Background:**

- 1998.3.-2005.2. **MD, Yonsei University College of Medicine, Seoul, Korea.**  
2008.3.-2018.8. **PhD, Yonsei Graduate School, Seoul, College of Medicine, Korea,**

- **Professional Experience:**

- 2005.3.-2006.2. **Internship, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea**  
2006.3.-2010.2. **Residency in Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea**  
2013.5.-2014.2 **Clinical Fellow, Division of Medical Oncology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea**  
2014.3-2015.8 **Clinical Research Professor, Division of Medical Oncology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea**  
2015.9.-2019.2 **Assistant Professor, Medical Oncology, CHA Bundang Medical Center, CHA University, Seongnam, Korea**  
2019.3.- **Associate Professor, Medical Oncology, CHA Bundang Medical Center, CHA University, Seongnam, Korea**  
**2019.8.-2020.2** **Deputy Chief of Research, CHA Bundang Medical Center, Seongnam, Korea**  
**2020.3.-** **Director of Cancer Center, CHA Bundang Medical Center, Seongnam, Korea**

• **Professional Organizations:**

Member, American Society of Clinical Oncology  
Member, American Association for Cancer Research  
Member, Korean Cancer Association  
Member, Korean Association for Clinical Oncology  
Member, Korean Cancer Study Group, Secretary of Hepatobiliary Pancreatic Cancer

• **Main Scientific Publications:**

1. Cheon JK\*, Chon HJ\*, Bang Y, Park NK, Shin JW, Kim KM, Lee Han Chu, Lee J, Yoo C, Ryoo BY. Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis *Liver Cancer 2020* (**\*Co-first author**)
2. Chon HJ, and C Kim. REACH-2: first biomarker-based anti-angiogenic therapy in patients with advanced hepatocellular carcinoma. *Chinese Clinical Oncology 2020*
3. Yang H, Lee WS, Kong SJ, Kim CG, Kim JH, Chang SK, Kim S, Kim G, Chon HJ\*, and C Kim. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade. *The Journal of Clinical Investigation 2019* (**\*Co-corresponding author**)
4. Chon HJ\*, Kim HJ\*, Noh JH, Yang HN, Lee WS, Kong SJ, Lee SJ, Lee YS, Kim WR, Kim JH, Kim, GI, and Kim C. STING signaling is a potential immunotherapeutic target in colorectal cancer. *Journal of Cancer 2019* (**\*Co-first author**)
5. Kim C\*, Chon HJ\*, Kim JH, Jung M, Nam JM, Kim HS, Kang B, Chung HC, Rha SY. Randomized phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer. *European Journal of Cancer 2019* (**\*Co-first author**)
6. Chon HJ\*, Lee WS\*, Yang H, Kong SJ, Lee NK, Moon ES, Choi J, Han EC, Kim JH, Ahn JB, Kim JH, Kim C. Tumor microenvironment remodeling by intratumoral oncolytic vaccinia virus enhances the efficacy of immune checkpoint blockade. *Clinical Cancer Research 2019*
7. Chon HJ\*, Kim C\*, Cho A, Kim YM, Jang SJ, Kim BO, Park CH, Hyung WJ, Ahn JB, Noh SH, Yun M, Rha SY. The Clinical Implications of FDG-PET/CT Differ According to Histology in Advanced Gastric Cancer. *Gastric Cancer 2019*